Technology Developed at Rutgers Sublicensed to Global Biopharmaceutical Company

Click for news Details
Faculty Referenced: Jin, Shengkan (Victor)

Base editing technology invented at Rutgers, The State University of New Jersey, and exclusively licensed to Revvity, Inc. subsidiary Horizon Discovery, has been sub-licensed to biopharmaceutical company AstraZeneca to support its creation of cell therapies for the treatment of cancer and immune-mediated diseases.

Rutgers is an equal access/equal opportunity institution. Individuals with disabilities are encouraged to direct suggestions, comments, or complaints concerning any accessibility issues with Rutgers web sites to: accessibility@rutgers.edu or complete the Report Accessibility Barrier or Provide Feedback Form.

Faculty & Research

News

Technology Developed at Rutgers Sublicensed to Global Biopharmaceutical Company